These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28700490)

  • 1. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study.
    Yang TW; Park HO; Jang HN; Yang JH; Kim SH; Moon SH; Byun JH; Lee CE; Kim JW; Kang DH
    Medicine (Baltimore); 2017 Jul; 96(28):e7482. PubMed ID: 28700490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects associated with the treatment of multidrug-resistant tuberculosis.
    Törün T; Güngör G; Ozmen I; Bölükbaşi Y; Maden E; Biçakçi B; Ataç G; Sevim T; Tahaoğlu K
    Int J Tuberc Lung Dis; 2005 Dec; 9(12):1373-7. PubMed ID: 16468160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistance pattern of Mycobacterium tuberculosis strains from patients with pulmonary and extrapulmonary tuberculosis during 2006 to 2013 in a Korean tertiary medical center.
    Lee HY; Lee J; Lee YS; Kim MY; Lee HK; Lee YM; Shin JH; Ko Y
    Korean J Intern Med; 2015 May; 30(3):325-34. PubMed ID: 25995663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.
    Swaminathan A; du Cros P; Seddon JA; Mirgayosieva S; Asladdin R; Dusmatova Z
    BMC Infect Dis; 2017 Jun; 17(1):417. PubMed ID: 28606115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
    Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
    PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in treatment outcomes of multidrug-resistant tuberculosis.
    Kwak N; Kim HR; Yoo CG; Kim YW; Han SK; Yim JJ
    Int J Tuberc Lung Dis; 2015 May; 19(5):525-30. PubMed ID: 25868019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
    Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
    Jaber AAS; Ibrahim B
    BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.
    Tola HH; Holakouie-Naieni K; Lejisa T; Mansournia MA; Yaseri M; Tesfaye E; Mola M
    PLoS One; 2019; 14(6):e0218487. PubMed ID: 31211809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.
    Shin SS; Hyson AM; Castañeda C; Sánchez E; Alcántara F; Mitnick CD; Fawzi MC; Bayona J; Farmer PE; Kim JY; Furin JJ
    Int J Tuberc Lung Dis; 2003 Apr; 7(4):347-53. PubMed ID: 12729340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
    Jo KW; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2014 Jan; 18(1):39-43. PubMed ID: 24365550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.